Robert Pelham Email & Phone Number

Senior biotechnology executive successful at providing global leadership for translational research, clinical biomarkers, and companion diagnostics (CDx) across solid tumor, hematological, metabolic, and autoimmune therapeutic areas using immuno-oncology (I/O), antibody-drug conjugates (ADCs), small-molecules, tumor-conditional biologics, and bi-specific T-cell engaging antibodies. Record of achievement in integrating computational biology, next generation sequencing, and genomics with clinical strategy to advance the development of CLIA-, CAP-, CE-, NMPA-, and FDA-cleared diagnostics. Track record as a pragmatic and effective direct-line manager of international teams. Accomplished at sponsor-side management of CROs and external academic and industry collaborations. Track record of high-impact scientific publications and presentations‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬. Former member of multiple NIH Study Sections with established professional network that enables communication with government agencies, national advisory boards, and key opinion leaders in the scientific community. Leader of successful regulatory interactions with FDA, CDRH, National Medical Products Administration of China (NMPA) and the Human Genetic Resources Administration of China (HGRAC). Proven success in developing and executing innovative programs supporting in vivo and in vitro IND-enabling studies, developing clinically validated in vitro diagnostics (IVD) and CDx for I/O and targeted therapies to enable FDA and NMPA registration across both solid tumors and hematological malignancies.

Listed skills include Oncology, Genomics, Molecular Biology, Bioinformatics, and 19 others.